Neurogene (NGNE) Current Leases (2018 - 2026)
Neurogene's (NGNE) quarterly Current Leases came in at $9000.0 in Q1 2026, down 81.25% YoY from $48000.0 in Q1 2025, and down 35.71% on a QoQ basis from $14000.0 in Q4 2025.
Neurogene (NGNE) Current Leases (2018 - 2026) Analysis & Trends
Neurogene (NGNE) has 9 years of Current Leases data on file, last reported at $9000.0 in Q1 2026.
- Quarterly Current Leases fell 81.25% year-over-year to $9000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9000.0 (down 81.25% YoY) and the FY2025 annual result came in at $14000.0, down 74.07% from the prior year.
- Current Leases slipped to $9000.0 in Q1 2026, from $14000.0 in the prior quarter.
- In the past five years, Current Leases ranged from a high of $3.1 million in Q2 2025 to a low of $4000.0 in Q3 2023.
- A 5-year average of $1.2 million and a median of $678000.0 in 2022 frame the typical range for Current Leases.
- Annual changes were most pronounced in 2023 — Current Leases tumbled 99.7% — and 2024, when it soared 71300.0%.
- Tracing NGNE's Current Leases over 5 years: stood at $678000.0 in 2022, then sank by 93.81% to $42000.0 in 2023, then gained by 28.57% to $54000.0 in 2024, then tumbled by 74.07% to $14000.0 in 2025, then tumbled by 35.71% to $9000.0 in 2026.
- The last three Current Leases figures came in at $9000.0 (Q1 2026), $14000.0 (Q4 2025), and $3.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Neurogene | 815.03 Mn | 815.03 Mn | - | 3.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.02 Mn |
| Mar 31, 2026 | 9,000.00 |
| Dec 31, 2025 | 14,000.00 |
| Sep 30, 2025 | 3.07 Mn |
| Jun 30, 2025 | 3.09 Mn |
| Mar 31, 2025 | 48,000.00 |
| Dec 31, 2024 | 54,000.00 |
| Sep 30, 2024 | 2.86 Mn |
| Jun 30, 2024 | 2.77 Mn |
| Mar 31, 2024 | 2.67 Mn |
| Dec 31, 2023 | 42,000.00 |
| Sep 30, 2023 | 4,000.00 |
| Jun 30, 2023 | 1.49 Mn |
| Mar 31, 2023 | 304,000.00 |
| Dec 31, 2022 | 678,000.00 |
| Sep 30, 2022 | 1.32 Mn |
| Jun 30, 2022 | 118,000.00 |
| Mar 31, 2022 | 1.22 Mn |
| Dec 31, 2021 | 1.17 Mn |
| Sep 30, 2021 | 104,000.00 |